Compounding pharmacies aren't FDA-approved, because that approval doesn't exist for them. Here's the regulatory split behind the copycat-Ozempic crackdown, and why claiming otherwise just got 25 telehealth firms in trouble.

The FDA's April 2026 proposal would end large-scale compounding of semaglutide and tirzepatide. Individual-patient compounding isn't affected, but the supply picture is about to shrink.

A trial in adults with HIV found semaglutide slowed one measure of biological aging by 9% versus placebo. Researchers call it an early signal, not evidence the drug reverses aging.